|  | Cancer | Lymphoma

Sentinel Lymph Node Mapping: Procedure, Benefits, Risks, and Role in Cancer Staging

Purpose

Sentinel lymph node biopsy (SLNB) identifies the first node(s) draining a primary tumor to assess nodal metastasis with minimal morbidity, replacing routine complete lymph node dissection (CLND) for clinically node-negative cancers.

Indications

  • Breast cancer (clinically node-negative).
  • Melanoma (Breslow thickness ≥0.8 mm or ulcerated).
  • Gynecologic cancers (endometrial, cervical, vulvar).
  • Penile cancer, Merkel cell carcinoma, others.

Procedure

  1. Preoperative lymphoscintigraphy (optional): Intradermal/peritumoral injection of 99mTc-sulfur colloid; dynamic imaging maps lymphatic drainage.
  2. Intraoperative injection: Blue dye (isosulfan blue, methylene blue) ± radioactive tracer around tumor or subareolar (breast).
  3. Detection: Gamma probe (radioactivity) + visual (blue dye) guide dissection to sentinel node(s).
  4. Excision & analysis: Node(s) removed; frozen section (intraoperative) or permanent pathology (H&E + IHC for cytokeratin/melanoma markers).
  5. Further management:
    • Negative SLN → no further nodal surgery (avoids CLND morbidity).
    • Positive SLN (macrometastasis >2 mm): Historically CLND; now often omitted in breast (Z0011 criteria) and melanoma (MSLT-II) with adjuvant systemic/radiation therapy.
    • Micrometastasis (0.2–2 mm) / ITCs (<0.2 mm): No CLND; consider adjuvant therapy per primary tumor biology.

Benefits

  • Accurate staging (95–98% negative predictive value).
  • Avoids CLND in ~70–80% of node-negative patients.
  • Reduces lymphedema risk (SLNB: 3–8% vs. CLND: 15–30% for axilla).
  • Less pain, neuropathy, seroma, shoulder dysfunction.
  • Outpatient procedure; quick recovery.

Risks & Limitations

  • False negative rate: 5–10% (obese, prior surgery, tumor location, tracer failure).
  • Allergic reaction to blue dye (rare, <1–2%; anaphylaxis possible).
  • Radiation exposure minimal (<1 mSv).
  • Technical failure (no node identified): proceed to CLND or axillary sampling.
  • Lymphedema still possible (though reduced).

Post-Procedure

  • Same-day discharge typical.
  • Pathology results in 3–7 business days.
  • Surgeon discusses results and adjuvant therapy plan (radiation, systemic).
  • Monitor for infection, seroma, neuropathy.

SLNB is a landmark de-escalation in surgical oncology—providing critical staging information while preserving quality of life. Ensure your surgeon performs SLNB routinely for indicated cancers.

Lymphoma - Related Articles